secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001104659-23-105964
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma dismisses EY as auditor, engages KPMG, effective Sep 28, 2023
----------------------------------------------------------------------------

- Audit Committee dismissed EY on Sep 28, 2023; EY's prior reports included a going-concern qualification.
- No disagreements with EY on accounting principles or audit scope during 2021-2022 or interim period.
- Board approved engagement of KPMG as independent auditor for fiscal year ending Dec 31, 2023.
- Neither the Company nor anyone on its behalf consulted KPMG on accounting matters prior to engagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923105964/0001104659-23-105964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923105964/tm2322367d5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-105964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer